358 patents
Page 8 of 18
Utility
Compounds and methods for modulating UBE3A-ATS
1 Mar 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A) in a cell or subject, and in certain instances increasing the expression of paternal UBE3A and the amount of UBE3A protein in a cell or subject.
Paymaan Jafar-nejad
Filed: 21 Apr 21
Utility
Compounds and Methods for Modulating PLP1
24 Feb 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PLP1 RNA in a cell or subject, and in certain instances reducing the amount of proteolipid protein 1 in a cell or subject.
Berit Elissa Powers
Filed: 29 Jun 21
Utility
Modulators of IRF5 Expression
17 Feb 22
The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF5 expression, which may be useful for treating, preventing, or ameliorating a disease associated with IRF5.
Susan M. FREIER
Filed: 3 Nov 21
Utility
Compositions and Their Uses Directed to Huntingtin
10 Feb 22
Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal.
Susan M. Freier
Filed: 21 Jun 21
Utility
Modulators of IRF4 expression
8 Feb 22
The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF4 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with IRF4.
Tianyuan Zhou, Youngsoo Kim, Robert MacLeod, Huynh-Hoa Bui, Susan M. Freier
Filed: 1 Mar 19
Utility
Compositions and Methods for Modulation of Lmna Expression
3 Feb 22
The present disclosure provides compounds comprising oligonucleotides complementary to a portion of the LMNA gene.
Priyam Singh, Frank Rigo, Tom Misteli, Madaiah Puttaraju
Filed: 20 Sep 19
Utility
Antisense compounds and uses thereof
1 Feb 22
The present invention provides compounds comprising oligonucleotides complementary to a pyruvate kinase M transcript.
Frank Rigo, C. Frank Bennett, Adrian R. Krainer, Zhenxun Wang
Filed: 2 Oct 18
Utility
Selective antisense compounds and uses thereof
1 Feb 22
The present invention provides oligomeric compounds.
Michael Oestergaard, Punit P. Seth, Eric E. Swayze
Filed: 18 Feb 20
Utility
Modulation of GYS1 expression
1 Feb 22
Provided herein are methods, compounds, and compositions for reducing expression of GYS1 in an individual.
Tamar R. Grossman, Susan M. Freier, Berge Minassian, Saija Ahonen
Filed: 19 Jun 17
Utility
Conjugated Antisense Compounds and Their Use
27 Jan 22
The present disclosure provides duplexes comprising a first oligomeric compound and a second oligomeric compound wherein the second oligomeric compound comprises a conjugate group.
Punit P. Seth, Michael Oestergaard, Eric E. Swayze
Filed: 10 Aug 21
Utility
Compounds and Methods for Reducing Prion Expression
27 Jan 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PRNP RNA in a cell or animal, and in certain instances reducing the amount of PrP protein in a cell or animal.
Susan M. Freier, Huynh-Hoa Bui, Hien Thuy Zhao
Filed: 21 Nov 19
Utility
Oligomer-conjugate Complexes and Their Use
27 Jan 22
Oligonucleotides, chemically-modified oligonucleotides, and oligonucleotide-conjugate complexes for use in research, diagnostics, and/or therapeutics are described herein.
Thazha P. Prakash, Eric E. Swayze, Walter F. Lima, Garth A. Kinberger
Filed: 1 Jul 21
Utility
Compounds and methods for reducing SNCA expression
25 Jan 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SNCA mRNA in a cell or animal, and in certain instances reducing the amount of alpha-synuclein protein in a cell or animal.
Holly Kordasiewicz, Tracy A. Cole
Filed: 9 Nov 18
Utility
Modulation of angiopoietin-like 3 expression
18 Jan 22
Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal.
Rosanne M. Crooke, Mark J. Graham, Richard Lee, Kenneth W. Dobie
Filed: 20 Dec 19
Utility
Compounds and Methods for Modulating Angiotensinogen Expression
6 Jan 22
Disclosed herein are compositions and compounds comprising modified oligonucleotides for modulating AGT and modulating a RAAS pathway related disease, disorder and/or condition in an individual in need thereof.
Adam Mullick, Mark J. Graham, Punit P. Seth, Susan M. Freier
Filed: 23 Nov 20
Utility
Modulators of YAP1 expression
4 Jan 22
The present embodiments provide methods, compounds, and compositions useful for inhibiting YAP1 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with YAP1.
Youngsoo Kim, Xiaolin Luo, Robert MacLeod, Susan M. Freier, Huynh-Hoa Bui
Filed: 31 Jan 20
Utility
Compounds and Methods for Modulation of Dystrophia Myotonica-protein Kinase (DMPK) Expression
30 Dec 21
Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal.
Eric E. Swayze, Susan M. Freier
Filed: 10 Feb 21
Utility
Modulators of IRF5 expression
28 Dec 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF5 expression, which may be useful for treating, preventing, or ameliorating a disease associated with IRF5.
Susan M. Freier
Filed: 15 Nov 19
Utility
Compositions and Methods for Modulating Apolipoprotein C-iii Expression
23 Dec 21
Provided herein are oligomeric compounds with conjugate groups targeting apolipoprotein C-III (ApoCIII).
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Mark J. Graham
Filed: 7 Dec 20
Utility
Modulation of the notch signaling pathway for treatment of respiratory disorders
14 Dec 21
Provided herein are methods, compounds, and compositions for modulating expression of at least one member of the Notch signaling pathway in a cell or individual.
Tamar R. Grossman
Filed: 17 Aug 18